Results 181 to 190 of about 144,436 (251)

IKKβ and USP28 Regulate HEY1 Stability to Promote Cancer Stemness and Immune Evasion in Hepatocellular Carcinoma

Advanced Science, EarlyView.
The uncovered IKKβ‐USP28‐HEY1 axis fuels cancer stemness and immune evasion in hepatocellular carcinoma. USP28 deubiquitinates HEY1 upon IKKβ‐mediated phosphorylation, conferring PD‐1/PD‐L1 blockade resistance. Pharmacological inhibition of USP28 sensitizes resistant tumors to anti‐PD‐1 immunotherapy, revealing a promising therapeutic strategy ...
Na Shao, Lin Zhang, Gufang Shen, Yangfan Lv, Tianshu Fang, Ya Cao, Qiongyi Zhang, Feng Xu, Chungang Liu   +8 more
wiley   +1 more source

How should immune checkpoint inhibitor myocarditis be treated? [PDF]

Cardiooncology
Badaan S, Abbass A, Tov S, Bar-Sela G, Bisharat N.   +4 more
europepmc   +1 more source

Targeting KDM3B Elicits Anti‐tumor Immunity by Alleviating SHP1–mediated STING Suppression in Triple–Negative Breast Cancer

Advanced Science, EarlyView.
P3FI–90 treatment targets KDM3B, reshapes the epigenetic landscape, and suppresses SHP1 expression, thereby activating STING–TBK1–IRF3–type I IFN signaling pathway. Consequently, CD8+ T cells are recruited to the tumor site and activated to produce IFN–γ and GZMB, leading to the killing of TNBC cells.
Xiaolong Wang, Wenhao Li, Yifei Wang, Ning Zhang, Bing Chen, Wenjing Zhao, Lijuan Wang, Dan Luo, Qifeng Yang   +8 more
wiley   +1 more source

Electrocardiographic changes in immune checkpoint inhibitor-associated cardiac injury: a narrative review. [PDF]

Cardiovasc Diagn Ther
Rao S, Wang G, Wu J, Ouyang J, Liu Z, Yang X, Luo D, Zhang S.   +7 more
europepmc   +1 more source

Synergistic Remodeling of Tumor Immune Microenvironment via a DNA Nanodevice Integrating STING Activation and Lysosome‐Targeted PD‐L1 Degradation

Advanced Science, EarlyView.
A rational design DNA nanoplatform not only achieves efficient PD‐L1 degradation but also triggers robust STING signaling. The nanodevice effectively reprograms “cold” tumors, leading to potent inhibition of tumor growth and metastasis in vivo. ABSTRACT The cGAS‐STING pathway is a cornerstone of innate antitumor immunity; however, its therapeutic ...
Haoxiang Li, Min Hou, Shasha Sun, Jun Cao, Jian‐Hui Jiang, Jianjun He   +5 more
wiley   +1 more source

Rituximab for the treatment of immune checkpoint inhibitor-induced glomerulonephritis. [PDF]

Clin Kidney J
Alasadi Y, Garcia JC, Arani N, Page V, Geng Y, Andersen CR, Tchakarov A, Kitchlu A, Mamlouk O, Abudayyeh A.   +9 more
europepmc   +1 more source

Combining Radiation‐Treated Tumor Vaccines With Mn‐MOF Nanoadjuvants to Amplify Radiation Induced Anti‐Tumor Immune Responses

Advanced Science, EarlyView.
Radiotherapy‐treated tumor membranes are integrated with Mn‐MOF nanoadjuvants to generate Mn@RM, a lymph node‐draining nanovaccine that delivers radiotherapy‐remodeled antigenic components. Mn@RM enhances dendritic cell activation, amplifies T cell‐mediated antitumor immunity, and synergizes with radiotherapy and PD‐1 blockade for combination cancer ...
Yiyu Wang, Qiqi Qi, Dezhong Li, Jingshi Tang, Weifeng Wang, Zushun Xu, Qi Xu, Fangfang Du, Qianyuan He   +8 more
wiley   +1 more source

Immune Checkpoint Inhibitor Pneumonitis Complicated by Invasive Pulmonary Aspergillosis in COPD: Diagnostic and Therapeutic Challenges. [PDF]

Clin Case Rep
Elendu C, Debua AT, Okolo EH, Sadiq HO.
europepmc   +1 more source

CEBPG‐Mediated Palmitic Acid Adaptation of Cancer‐Associated Fibroblasts Drives Metastasis of Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
This study reveals a metabolic signaling axis in the OSCC microenvironment where palmitic acid (PA) drives the activation of CAFs. PA uptake triggers CEBPG‐dependent epigenetic remodeling to upregulate ERN1 and TMBIM6, thereby mitigating ER stress. This adaptive program sustains CAF survival and the pro‐metastatic phenotype, establishing this pathway ...
Yiling Duan, Yitong Li, Yufei Wu, Xiao Yang, Rui Li, Hui Zhao, Zhengjun Shang   +6 more
wiley   +1 more source

Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patients. [PDF]

ESMO Open
Kleinberger M, Sunder-Plassmann V, Starzer AM, Tomasich E, Zierfuss C, Niederdorfer B, Berger JM, Gottmann L, Solano Henao I, Korpan M, Fuerst J, Feldmann K, Englisch C, Ay C, Haslacher H, Furtner J, Preusser M, Heller G, Berghoff AS.   +18 more
europepmc   +1 more source